Claims
- 1. A method of alleviating symptoms of diabetes, comprising the step of administering the combination of anti-glutamic acid decarboxylase (anti-GAD) antibody and anti-insulin antibody in amounts effective to alleviate symptoms of diabetes.
- 2. The method of claim 1, wherein the symptoms are selected from the group consisting of elevated blood sugar level, elevated hemoglobin A1c level, neuropathy, retinopathy, ketoacidosis, and glycosuria.
- 3. The method of claim 1 wherein both anti-GAD and anti-insulin antibodies are monoclonal antibodies.
- 4. The method of claim 1 wherein the administration step is oral.
- 5. The method of claim 4 wherein the administration step is sublingual.
- 6. The method of claim 4 wherein both anti-GAD and anti-insulin antibodies are administered in an enterically protected form.
- 7. The method of claim 1 wherein the administration step is by injection.
- 8. The method of claim 7 wherein the administration step is by subcutaneous injection.
- 9. The method of claim 1 comprising less than 1.0 mg of anti-GAD antibodies and less than 1.0 mg of anti-insulin antibodies.
- 10. The method of claim 9 comprising less than 0.1 mg of anti-GAD antibodies and less than 0.1 mg of anti-insulin antibodies.
- 11. The method of claim 9 comprising from 1×10−6 to 1×10−2 mg of anti-GAD antibodies and 1×10−6 to 1×10−2 mg of anti-insulin antibodies.
- 12. The method of claim 9 comprising from 1×10−5 to 1×10−3 mg of anti-GAD antibodies and 1×10−5 to 1×10−3 mg of anti-insulin antibodies.
- 13. A pharmaceutical composition for administration to a subject for alleviating symptoms of diabetes comprising less than 1.0 mg of anti-GAD antibodies and less than 1.0 mg of anti-insulin antibodies.
- 14. A pharmaceutical composition of claim 13 comprising less than 0.1 mg of anti-GAD antibodies and less than 0.1 mg of anti-insulin antibodies.
- 15. A pharmaceutical composition of claim 13 comprising from 1×10−6 to 1×10−2 mg of anti-GAD antibodies and 1×10−6 to 1×10−2 mg of anti-insulin antibodies.
- 16. A pharmaceutical composition of claim 13 comprising from 1×10−5 to 1×10−3 mg of anti-GAD antibodies and 1×10−5 to 1×10−3 mg of anti-insulin antibodies.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. application Ser. No. 09/774,770 filed on Jan. 31, 2001 and issued ______ as U.S. Pat. No. ______, which is a continuation-in-part of U.S. application Ser. No. 09/514,993 filed on Feb. 29, 2000 and issued Feb. 13, 2001 as U.S. Pat. No. 6,187,309, which claims benefit of U.S. Provisional Application Serial No. 60/153,838 filed on Sep. 14, 1999; the disclosures of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60153838 |
Sep 1999 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09774770 |
Jan 2001 |
US |
Child |
09918343 |
Jul 2001 |
US |
Parent |
09514993 |
Feb 2000 |
US |
Child |
09774770 |
Jan 2001 |
US |